Head-To-Head Comparison: Amylyx Pharmaceuticals (NASDAQ:AMLX) and Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ:CLLS) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Valuation and Earnings

This table compares Cellectis and Amylyx Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59 million	1.72	-$67.59 million	($0.65)	-2.10
Amylyx Pharmaceuticals	N/A	N/A	-$144.74 million	($1.44)	-21.51

Cellectis has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cellectis has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500.

Profitability

This table compares Cellectis and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Amylyx Pharmaceuticals	N/A	-41.54%	-38.91%

Analyst Recommendations

This is a summary of current ratings and target prices for Cellectis and Amylyx Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	2	2	2	1	2.29
Amylyx Pharmaceuticals	1	0	6	2	3.00

Cellectis currently has a consensus target price of $5.46, suggesting a potential upside of 300.00%. Amylyx Pharmaceuticals has a consensus target price of $43.71, suggesting a potential upside of 41.10%. Given Cellectis’ higher probable upside, equities analysts clearly believe Cellectis is more favorable than Amylyx Pharmaceuticals.

Institutional & Insider Ownership

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cellectis beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Cellectis

Cellectis is a biotechnology company focused on developing gene-edited cell and gene therapies, with an emphasis on treatments for cancer. Founded in France in 1999, the company operates in France and the United States. Its research centers on TALEN gene-editing technology, which it uses to modify cells for potential therapeutic applications. Cellectis is developing allogeneic CAR T-cell therapies made from donor T cells, an approach intended to create treatments that can be prepared for use by multiple patients rather than made individually for each patient.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.